Department of Human Genetics, The University of Chicago, Chicago, Illinois, United States of America.
PLoS One. 2010 Apr 16;5(4):e10174. doi: 10.1371/journal.pone.0010174.
Current diagnostics for allergies, such as skin prick and radioallergosorbent tests, do not allow for inexpensive, high-throughput screening of patients. Additionally, extracts used in these methods are made from washed pollen that lacks pollen surface materials that may contain allergens.
METHODOLOGY/PRINCIPAL FINDINGS: We sought to develop a high-throughput assay to rapidly measure allergen-specific IgE in sera and to explore the relative allergenicity of different pollen fractions (i.e. surface, cytoplasmic, commercial extracts). To do this, we generated a protein microarray containing surface, cytoplasmic, and commercial extracts from 22 pollen species, commercial extracts from nine non-pollen allergens, and five recombinant allergenic proteins. Pollen surface and cytoplasmic fractions were prepared by extraction into organic solvents and aqueous buffers, respectively. Arrays were incubated with <25 uL of serum from 176 individuals and bound IgE was detected by indirect immunofluorescence, providing a high-throughput measurement of IgE. We demonstrated that the allergen microarray is a reproducible method to measure allergen-specific IgE in small amounts of sera. Using this tool, we demonstrated that specific IgE clusters according to the phylogeny of the allergen source. We also showed that the pollen surface, which has been largely overlooked in the past, contained potent allergens. Although, as a class, cytoplasmic fractions obtained by our pulverization/precipitation method were comparable to commercial extracts, many individual allergens showed significant differences.
CONCLUSIONS/SIGNIFICANCE: These results support the hypothesis that protein microarray technology is a useful tool for both research and in the clinic. It could provide a more efficient and less painful alternative to traditionally used skin prick tests, making it economically feasible to compare allergen sensitivity of different populations, monitor individual responses over time, and facilitate genetic studies on pollen allergy.
目前的过敏诊断方法,如皮肤点刺和放射过敏原吸附试验,无法进行经济高效的高通量患者筛选。此外,这些方法中使用的提取物是从经过洗涤的花粉中提取的,缺乏可能含有过敏原的花粉表面物质。
方法/主要发现:我们试图开发一种高通量测定法,快速测量血清中的过敏原特异性 IgE,并探索不同花粉成分(即表面、细胞质、商业提取物)的相对变应原性。为此,我们生成了一个包含 22 种花粉物种的表面、细胞质和商业提取物、9 种非花粉过敏原的商业提取物以及 5 种重组过敏原蛋白的蛋白质微阵列。花粉的表面和细胞质部分分别通过有机溶剂和水性缓冲液提取来制备。用来自 176 个人的<25μL 血清孵育阵列,通过间接免疫荧光检测结合的 IgE,从而实现 IgE 的高通量测量。我们证明了过敏原微阵列是一种可重复性方法,可以在少量血清中测量过敏原特异性 IgE。使用这种工具,我们证明了特异性 IgE 根据过敏原来源的系统发育聚类。我们还表明,花粉表面在过去很大程度上被忽视了,但它含有有效的过敏原。尽管我们通过粉碎/沉淀法获得的细胞质部分作为一类与商业提取物相当,但许多个别过敏原显示出显著差异。
结论/意义:这些结果支持了蛋白质微阵列技术是研究和临床应用的有用工具的假设。它可以提供一种比传统皮肤点刺试验更高效、更无痛的替代方法,使比较不同人群的过敏原敏感性、随时间监测个体反应以及促进花粉过敏的遗传研究成为经济可行的方法。